TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07794735: Multicenter, Prospective, Open-Label Trial to Evaluate PK, Safety, and Tolerability of TAK-664 in IG Treatment-Naïve Participants With Primary Immunodeficiency Diseases

Sponsor: Takeda · Phase: PHASE4 · Area: IMMUNOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,222,800

Rescue Site Savings

+$2,787,600

Unlock Full NCT07794735 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07794735 Rescue Dossier →